ISOLATED POLYPEPTIDES BASED ON NEUTRALISING OF PROTEIN p17 OF HIV VIRUS, USED AS VACCINES, AND NEUTRALISING ANTI-p17-ANTIBODIES, SPECIFICALLY RECOGNISING SAID NEUTRALISING Russian patent published in 2008 - IPC C07K14/16 C07K16/08 A61K38/10 A61K39/12 A61P31/18 

FIELD: chemistry, pharmaceutics.

SUBSTANCE: invention relates to immunology and biotechnology. Described is polypeptide of protein P17 of HIV virus with amino acid sequence, consisting of peptide, corresponding to neutralising epitope of protein p17 of HIV, and peptide, corresponding to positions 23-32 of protein p17 of HIV. Peptide is bound to peptide of neutralising in carboxy-terminal position of epitope and makes it soluble. Described are vaccine compositions based on polypeptide, versions of polypeptide application such as, for preparation of medication against HIV, and as specific reagent in test on detecting neutralising anti-p-17-antibodies. Described are monoclonal and polyclonal anti-p 17-antibodies, able to recognise neutralising polypeptide epitope in specific way and neutralise its biological activity. Described is application of said antibodies to polypeptide for detecting p17 in biological material and for preparation of medication inhibiting p17 protein activity in HIV-infected people. Application of invention allows to induce neutralising anti- p17-antibodies and inhibit p17 activity which can be applied in medicine for preparation of vaccine of injection material against HIV.

EFFECT: obtaining composition which can be applied in medicine for preparation of vaccine or injection material against HIV.

17 cl, 9 ex